Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Assets (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Assets readings, the most recent being $30.1 million for Q4 2025.

  • On a quarterly basis, Assets fell 1.57% to $30.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.1 million, a 1.57% decrease, with the full-year FY2025 number at $30.1 million, down 1.57% from a year prior.
  • Assets hit $30.1 million in Q4 2025 for Sunshine Biopharma, down from $31.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $42.0 million in Q2 2022 to a low of $1.8 million in Q2 2021.
  • Median Assets over the past 5 years was $29.2 million (2022), compared with a mean of $24.4 million.
  • Biggest five-year swings in Assets: skyrocketed 2818.08% in 2021 and later crashed 32.34% in 2023.
  • Sunshine Biopharma's Assets stood at $2.2 million in 2021, then skyrocketed by 1227.52% to $29.2 million in 2022, then dropped by 6.49% to $27.3 million in 2023, then rose by 11.75% to $30.6 million in 2024, then dropped by 1.57% to $30.1 million in 2025.
  • The last three reported values for Assets were $30.1 million (Q4 2025), $31.5 million (Q3 2025), and $32.0 million (Q2 2025) per Business Quant data.